
Natera (NTRA) Stock Forecast & Price Target
Natera (NTRA) Analyst Ratings
Bulls say
Natera Inc is positioned for a positive financial trajectory due to significant gross margin (GM) expansion, driven by a strong clinical volume growth of its Signatera test, with a projected 60% increase in 2024 alongside rising average selling prices (ASPs) resulting from enhanced payor coverage. The company's gross margins have notably improved from the low 40s to approximately 60%, facilitated by a mix of higher-priced tests, increased reimbursement rates, and more recognized prices per test, indicating a robust operational framework for sustained growth. Furthermore, Natera's strategic advancements in its molecular residual disease (MRD) portfolio and its leadership in non-invasive prenatal testing (NIPT) place it advantageously within a substantial market opportunity, reinforcing its ability to navigate the evolving landscape of cancer screening and diagnostics.
Bears say
Natera's financial outlook appears negative primarily due to weaker-than-expected volume performance in the fourth quarter, compounded by disruptions from electronic medical record (EMR) integration and seasonal factors. The company's 2025 revenue guidance falls short of consensus estimates by approximately $28.3 million at the midpoint, indicating potential challenges in achieving profitability, especially if payors reduce or eliminate reimbursement for its products and services. Additionally, margin erosion is expected due to decreasing average selling prices (ASP) of Panorama and ongoing pricing pressures from expanding payor networks, which could further impact the company's revenue trajectory.
This aggregate rating is based on analysts' research of Natera and is not a guaranteed prediction by Public.com or investment advice.
Natera (NTRA) Analyst Forecast & Price Prediction
Start investing in Natera (NTRA)
Order type
Buy in
Order amount
Est. shares
0 shares